Last edition
News about "Selumetinib granted orphan drug designation in Jap"
Selumetinib granted orphan drug designation in Japan for neurofibromatosis type 1
AstraZeneca today announced that selumetinib has been granted orphan drug designation (ODD) in Japan for the treatment of neurofibromatosis type 1 (NF1), a rare and debilitating genetic disease
Selumetinib Granted Orphan Drug Designation In Jap | 01/07/2020 | By Darshana | 380
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members